United States v. Little

CourtCourt of Appeals for the Fifth Circuit
DecidedNovember 3, 2023
Docket21-11225
StatusUnpublished

This text of United States v. Little (United States v. Little) is published on Counsel Stack Legal Research, covering Court of Appeals for the Fifth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
United States v. Little, (5th Cir. 2023).

Opinion

Case: 21-11225 Document: 00516956725 Page: 1 Date Filed: 11/03/2023

United States Court of Appeals for the Fifth Circuit United States Court of Appeals Fifth Circuit

____________ FILED November 3, 2023 No. 21-11225 Lyle W. Cayce ____________ Clerk

United States of America,

Plaintiff—Appellee,

versus

Tammie L. Little; Laila N. Hirjee, Medical Doctor,

Defendants—Appellants,

consolidated with _____________

No. 21-11228 _____________

Mark E. Gibbs, Medical Doctor,

Defendant—Appellant. Case: 21-11225 Document: 00516956725 Page: 2 Date Filed: 11/03/2023

______________________________

Appeals from the United States District Court for the Northern District of Texas USDC Nos. 3:17-CR-103-12, 3:17-CR-103-5 and 3:17-CR-103-6 ______________________________

Before Richman, Chief Judge, and Stewart and Douglas, Circuit Judges. Per Curiam: * Three codefendants appeal their various convictions stemming from a multi-million-dollar healthcare conspiracy that involved fraudulent certification and recertification of patients as terminally ill and eligible for hospice care. Finding no reversible error, we affirm. I Defendants challenge the sufficiency of the evidence to support their convictions. Our sufficiency review is highly deferential to the jury’s verdict, and “[a]s a result, the recounting of the evidence that follows is in the light most favorable to the jury’s verdict.” 1 Novus was a hospice provider located in Dallas, Texas, and co- founded by Bradley Harris (Harris) and Amy Harris (Amy Harris) in 2012. Harris oversaw Novus’s operations. Drs. Mark E. Gibbs and Laila N. Hirjee were medical directors for Novus. Tammie L. Little was a registered nurse (RN). Melanie Murphey was an administrator who had no medical training.

_____________________ * This opinion is not designated for publication. See 5th Cir. R. 47.5. 1 United States v. Mesquias, 29 F.4th 276, 279 (5th Cir.) (citing United States v. Moreno–Gonzalez, 662 F.3d 369, 372 (5th Cir. 2011)), cert. denied sub nom. McInnis v. United States, 143 S. Ct. 115 (2022), and cert. denied sub nom. Mesquias v. United States, 143 S. Ct. 269 (2022).

2 Case: 21-11225 Document: 00516956725 Page: 3 Date Filed: 11/03/2023

No. 21-11225 c/w No. 21-11228

Under applicable regulations, hospice is a service for the “terminally ill” that provides palliative care rather than curative care. “Terminally ill” means “that the individual has a medical prognosis that his or her life expectancy is 6 months or less if the illness runs its normal course.” 2 Hospice care is among the benefits covered by Medicare. Medicare pays hospice providers’ claims automatically in order to expedite reimbursement. A web of statutes and regulations governs whether Medicare will pay for hospice services. For a hospice claim to be eligible for Medicare reimbursement, a medical director must have enrolled the patient after “certify[ing] in writing . . . that the individual is terminally ill . . . based on the physician’s or medical director’s clinical judgment regarding the normal course of the individual’s illness.” 3 The medical director can rely on the records and recommendation of the patient’s attending physician to certify a patient as terminally ill and admit him or her to hospice. A patient can be recertified after their first 90 days on hospice without a face-to-face visit. If a patient is still alive after 180 days, Medicare requires that a face-to-face visit accompany the medical director’s recertification for hospice. A face-to-face visit is also required for every following recertification, which must occur no more than 60 days after the previous one. Novus exploited Medicare’s reimburse-first-verify-later system. Because Medicare pays a flat rate per day for patients who are receiving hospice care regardless of the amount of care provided or the resulting costs to the hospice, it can be profitable to have low-acuity patients who are designated as hospice patients for long periods of time. Novus’s business model was to target patients who had a medical diagnosis that would qualify

_____________________ 2 42 C.F.R. § 418.3. 3 42 U.S.C. § 1395f(a)(7)(A)(i)(II).

3 Case: 21-11225 Document: 00516956725 Page: 4 Date Filed: 11/03/2023

them for hospice but who were not “imminently dying.” Staff at Novus would market to these desirable types of patients, and, if those patients agreed to receive hospice services from Novus, the staff would then use pre- signed physician’s orders to enroll patients. As discussed above, Medicare has certain requirements for recertifying patients for hospice. Relevant here, the medical director’s 180- day recertification must be accompanied by a form attesting to the medical director’s face-to-face visit with the patient and a physician’s narrative explaining “why the clinical findings of that face-to-face encounter support a life expectancy of six months or less.” At Novus, the medical directors used nurses’ notes to fill out the narrative section of the face-to-face forms, and Harris told them what dates to put on the forms. Face-to-face visits by the directors did not occur. Ultimately, Novus’s business model had inherent limitations. Medicare imposes an aggregate cap on the amount of money it will pay a hospice in a year. When Medicare has paid a hospice provider more than its cap allows, it claws back the excess payments. Novus exceeded its cap in 2012 and 2013, and, by its calculations, it had exceeded its cap by millions in mid-2014. To avoid liability for the excess payments, Novus needed to increase the number of patients who were hospice patients for a short time. Bluntly, Novus needed patients who would die quickly or who could be discharged before the end of their first 90-day benefits period. To meet these needs, Harris entered into an agreement with Ali Rizvi, the owner of Express Medical. Rizvi provided Little with login credentials to Express Medical’s electronic records database. Little and Harris used Express Medical’s database to look for patients who had been diagnosed with a disease that would qualify them for hospice care. Little or Amy Harris would then contact those patients and try to enroll them with Novus.

4 Case: 21-11225 Document: 00516956725 Page: 5 Date Filed: 11/03/2023

In 2015, the Centers for Medicare and Medicaid Services (CMS) suspended payments to Novus because of “credible allegations of fraud.” Harris, Amy Harris, and Dr. Gibbs responded by transferring some of Novus’s patients to another hospice company, Dependable. Dr. Gibbs served as Dependable’s medical director until CMS suspended payments to Dependable. A grand jury indicted Harris, Amy Harris, Rizvi, Murphey, Dr. Gibbs, Dr. Hirjee, Little, and others for conspiracy to commit healthcare fraud and other crimes. Little and Drs. Hirjee and Gibbs proceeded to trial. Harris and Murphey, among others who had been indicted, pled guilty and testified at trial. The jury found each defendant guilty of the allegations in Count One, conspiracy to commit healthcare fraud. The jury also found: (1) Dr. Gibbs guilty of Counts Five and Six, substantive healthcare fraud, but acquitted him on a third count, and guilty of Count Fifteen, conspiracy to obstruct an administrative proceeding; (2) Dr. Hirjee guilty of Counts Eight, Nine, and Ten, substantive healthcare fraud, and guilty of Count Fourteen, unlawful distribution of a controlled substance; and (3) Little guilty of Counts Two, Three, and Four, substantive healthcare fraud. The district court sentenced Dr. Gibbs to 156 months of imprisonment; Dr. Hirjee to 120 months; Little to 33 months. The district court ordered Dr.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

United States v. Pace
10 F.3d 1106 (Fifth Circuit, 1993)
United States v. Zuniga
18 F.3d 1254 (Fifth Circuit, 1994)
United States v. Asibor
109 F.3d 1023 (Fifth Circuit, 1997)
United States v. Dupre
117 F.3d 810 (Fifth Circuit, 1997)
United States v. Huerta
182 F.3d 361 (Fifth Circuit, 1999)
United States v. Clark
193 F.3d 845 (Fifth Circuit, 1999)
United States v. Miranda
248 F.3d 434 (Fifth Circuit, 2001)
United States v. Daniels
252 F.3d 411 (Fifth Circuit, 2001)
United States v. Harris
293 F.3d 863 (Fifth Circuit, 2002)
United States v. Guidry
406 F.3d 314 (Fifth Circuit, 2005)
United States v. Villanueva
408 F.3d 193 (Fifth Circuit, 2005)
Johnson v. Pettiford
442 F.3d 917 (Fifth Circuit, 2006)
United States v. Lares-Meraz
452 F.3d 352 (Fifth Circuit, 2006)
United States v. Martinez-Vega
471 F.3d 559 (Fifth Circuit, 2006)
United States v. Fields
483 F.3d 313 (Fifth Circuit, 2007)
United States v. Dillon
532 F.3d 379 (Fifth Circuit, 2008)
United States v. Klein
543 F.3d 206 (Fifth Circuit, 2008)
United States v. Armstrong
550 F.3d 382 (Fifth Circuit, 2008)
United States v. Brown
553 F.3d 768 (Fifth Circuit, 2008)
United States v. Percel
553 F.3d 903 (Fifth Circuit, 2008)

Cite This Page — Counsel Stack

Bluebook (online)
United States v. Little, Counsel Stack Legal Research, https://law.counselstack.com/opinion/united-states-v-little-ca5-2023.